Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

The Ebola virus disease outbreak in the Democratic Republic of the Congo (DRC) has reached 1,203 confirmed cases, including 321 deaths, according to the latest report from the country's public health authorities.

The report said 148 patients have recovered, while 419 remain in isolation or are receiving hospital care. Health authorities have also identified 265 suspected cases, including 77 deaths.

WHO Warns Fight Is Far From Over

World Health Organization Director-General Tedros Adhanom Ghebreyesus said on X that contact tracing in the DRC is reaching more people and more Ebola patients are recovering and returning home.

However, he warned that the fight is "far from over."

"War and insecurity still slow the response, and mistrust is the real battleground. Win trust, and we win this," he said.

Also read: Jeremy Doku Row: Doctors Explain Why Fathers Play A Crucial Role During Childbirth

Nearly 300 Confirmed Patients Unaccounted For

The whereabouts of nearly 300 people who tested positive for Ebola remain unknown, according to Africa's top public health official.

The figures on recoveries, patients in treatment and deaths indicate that 297 confirmed cases are currently unaccounted for.

"This is a concern that we have. Where are these people?" Dr Jean Kaseya, Director General of the Africa Centers for Disease Control andPrevention (Africa CDC), was quoted as saying by The Guardian.

He added that the ongoing humanitarian crisis and conflict in affected areas have left more than one million people living in camps that health workers cannot access.

WHO Projects More Than 8,000 Cases

Read More: Ebola Outbreak: The Unique Symptoms Seen In Patients Infected With Bundibugyo

The current outbreak, caused by the Bundibugyo strain, was officially declared on May 15.

As per projections published by the World Health Organization's Africa regional office in The Lancet Infectious Diseases estimate that the outbreak could reach about 8,210 cases and 1,420 deaths by mid-September.

Clinical Trials Set To Begin

The first trial of drugs that may treat the Bundibugyo virus is expected to begin in the DRC next week. A separate trial testing an antiviral drug to prevent infection among close contacts is scheduled to start a week later.

The outbreak is being driven by the rare Bundibugyo strain, for which there are currently no approved vaccines or treatments.

Scientists working to develop vaccines and therapies say progress is being slowed by the lack of a viable virus sample.

US CDC Raises Response To Highest Level

Meanwhile, the US CDC raised its response to the Ebola outbreak in the Congo to its highest level, but said the risk of the disease spreading in the US remained low.

The move, reserved for the most severe health crises, signals growing concern over the rare strain's rapid spread.

The Centers for Disease Control and Prevention raised its emergency activation to Level 1. It is the most severe designation, which is reserved for critical emergencies and assigns the largest number of staff possible to work the response.

The CDC has also deployed 19 staff members overseas to assist its country teams with the response, Dr Satish Pillai, incident manager for the CDC's Ebola response, said ⁠in a press briefing.

The CDC is also providing financial resources to partners on the ground and has trained 25 local field epidemiologists who can operate in areas that CDC staff cannot access.

India has joined the Global Antibiotic Research and Development Partnership (GARDP)-led NeoSep1 clinical trial, a landmark international study evaluating new antibiotic treatments for newborns with drug-resistant sepsis.

Sepsis is the second leading cause of neonatal mortality in India after prematurity and low birth weight, accounting for an estimated 30–40 per cent of all newborn deaths.

The NeoSep1 trial began in India with the first baby enrolled at the Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) in Puducherry, followed by Pt. B.D. Sharma PGIMS in Rohtak. Lokmanya Tilak Municipal Medical College and General Hospital in Mumbai is also expected to begin enrolling newborns soon.

"Every day doctors face the heartbreaking reality of losing babies to sepsis due to lack of safe and effective treatments," said Dr Nishad Plakkal, Principal Investigator of the NeoSep1 trial in India and Associate Dean (Research) and Professor and Head of the Department of Neonatology at JIPMER.

"Having the right antibiotics at the right dose can tip the balance between life and death. This trial offers hope to change that," Plakkal added.

"The trial will give neonatologists new tools, and give babies with sepsis a fighting chance at life," said Sally Ellis, who leads GARDP's Children's Antibiotics Program.

Why Newborns Are At Greater Risk

Also read:US Woman Nearly Died After Brushing Off Sepsis Symptoms As Flu

According to Ellis, newborns are particularly vulnerable to life-threatening sepsis because of their underdeveloped immune systems.

The growing burden of antibiotic resistance in low- and middle-income countries (LMICs) has further worsened the problem by reducing the effectiveness of standard treatments. Studies have reported extremely high resistance to the combination of ampicillin and gentamicin, the antibiotic regimen currently recommended by the World Health Organization for the initial treatment of neonatal sepsis.

"Today, we stand at a tipping point. The antibiotics for newborns that we have relied on for decades are failing against resistant infections in many hospital settings," Ellis said.

What Is The NeoSep1 Trial?

Read More: Andhra Pradesh To Launch Rare Disease Policy, Expand Universal Newborn Screening

An estimated 3 million newborns develop sepsis every year. The condition occurs when the body's response to an infection triggers widespread inflammation, potentially leading to tissue damage, organ failure, and death. More than 90% of neonatal sepsis deaths occur in low- and middle-income countries.

The NeoSep1 trial aims to identify safe and effective antibiotic regimens that can reduce deaths caused by drug-resistant neonatal sepsis.

The first phase of the study, conducted in South Africa and Kenya in 2023, validated the appropriate doses of fosfomycin and flomoxef when used in combination with other antibiotics in newborns.

The second phase is using a Personalised Randomised Controlled Trial (PRACTical) design to evaluate and rank multiple antibiotic regimens for newborns with sepsis. The approach is expected to help clinicians choose the most effective treatments based on local patterns of antibiotic resistance while also informing future national and international treatment guidelines.

The NeoSep1 trial is expected to enroll 3,000 newborns across Asia and Africa by the end of 2028.

Along with India, newborns have already been enrolled in Ghana, Kenya, and South Africa. Hospitals in Vietnam, Pakistan, Malaysia, Bangladesh, and Uganda are also expected to join the study.

Warning Signs of Sepsis

Sepsis is a life-threatening reaction to an infection that harms the immune system, tissues, and organs. It can lead to organ failure or death if not treated urgently, according to the Cleveland Clinic.

According to Sepsis Alliance, the acronym TIME can help people recognize potential warning signs of sepsis and seek urgent medical care.

T — Temperature: Body temperature is unusually high or low.

I — Infection: Signs or symptoms of an infection are present.

M — Mental Decline: Confusion, excessive sleepiness, or difficulty waking up.

E — Extremely Ill: Severe pain, extreme discomfort, or shortness of breath.

The highly pathogenic H5N1 bird flu virus has now spread to a second Australian state. Less than a week after it was first identified in two seabirds in Western Australia, authorities have confirmed another case in South Australia.

For the general public, the health risk remains low. Experts say people who don't regularly handle infected birds or animals are unlikely to contract the virus. However, Australia's poultry industry is treating the situation with extreme caution.

If the virus were to reach commercial poultry farms, the consequences could be severe. Millions of chickens and other birds could either die from the disease or be culled to stop it from spreading. Such an outbreak could also trigger export restrictions on Australian poultry products and leave farmers facing massive cleanup and recovery costs, even with government assistance.

So far, there is no evidence that H5N1 has entered any commercial poultry farms or Australia's native wild bird populations. The confirmed cases have been limited to wild seabirds.

Even so, poultry producers across the country—particularly in Western Australia and South Australia—are already tightening biosecurity measures to reduce the risk of the virus reaching their flocks.

Also Read: New Oral GLP-1 Pill Delivers Major Weight Loss In Just 36 Weeks

Australia's largest poultry producer, Inghams, has restricted access to its Western Australian farms, allowing only essential personnel to enter. The company has also requested permission from the federal government's Chief Veterinary Officer to temporarily move its free-range birds indoors. The aim is to reduce any contact between domestic poultry and wild birds, which are considered the most likely source of infection.

These additional precautions build on the strict biosecurity rules already followed by the poultry industry. Farm visits are kept to a minimum, employees are generally prohibited from keeping backyard chickens or other birds at home, and workers are discouraged from moving between different poultry facilities within a short period. Many farms also require staff to shower before entering, change into company-issued clothing, and follow rigorous hygiene procedures. Measures to keep wild birds away and control rodents and insects are also a standard part of farm management.

The H5N1 strain is particularly deadly for chickens, as well as turkeys and quail. Ducks can also become infected, but they present a different challenge because they may carry and spread the virus without showing obvious signs of illness, making them especially difficult to monitor.

Why Australia Had Remained Bird Flu-Free

Until now, Australia was the only continent where the H5N1 strain, the highly contagious strain of H5 bird flu, had not been detected. Although the virus has circulated across Asia since the 1990s and reached Antarctica in 2024, Australia had remained unaffected.

According to Dr Michelle Wille, ARC Future Fellow at the University of Melbourne, Australia's unique bird migration patterns likely delayed the virus's arrival.

"There are no duck species which routinely migrate between Australia and Asia, nor are there ducks that migrate through Antarctica," Wille wrote in The Conversation.

However, evidence suggests other seabirds—including gulls, skuas and giant petrels—may have helped carry the virus over long distances across Antarctica and subantarctic regions, eventually bringing it closer to Australia, he said.

As per the latest update, Australian scientists believe that the H5 bird flu strain killed more than 13,000 elephant seal pups after infecting a breeding colony on the remote Heard and McDonald Islands, one of Australia's external territories in the sub-Antarctic.